Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 23, Issue 6, pp. 1542-1551
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 19, 2016
- Revision received August 11, 2016
- Accepted September 5, 2016
- Published first September 23, 2016.
Article Versions
- Previous version (September 23, 2016 - 09:47).
- Previous version (January 18, 2017 - 12:19).
- You are viewing the most recent version of this article.
Copyright & Usage
©2016 American Association for Cancer Research.
Author Information
- Iris Sze Ue Luk1,2,
- Raunak Shrestha1,
- Hui Xue1,2,
- Yuwei Wang2,
- Fang Zhang2,
- Dong Lin1,2,
- Anne Haegert1,
- Rebecca Wu2,
- Xin Dong2,
- Colin C. Collins1,3,
- Amina Zoubeidi1,3,
- Martin E. Gleave1,3,
- Peter W. Gout2, and
- Yuzhuo Wang1,2,3,*
- 1Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
- 2Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, British Columbia, Canada.
- 3Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- ↵*Corresponding Author:
Yuzhuo Wang, Department of Experimental Therapeutics, BC Cancer Agency, 675 West 10th Ave, Vancouver, British Columbia V5Z 1L3, Canada. Phone: 604-675-8013; Fax: 604-675-8019; E-mail: ywang{at}bccrc.ca
March 2017
Volume 23, Issue 6
Volume 23, Issue 6
BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer
Jump to section
Advertisement